Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Claudio Procaccianti"'
Autor:
Carsten Schwarz, Claudio Procaccianti, Laura Costa, Riccardo Brini, Richard Friend, Grazia Caivano, Hosein Sadafi, Charles Mussche, Nicolas Schwenck, Michael Hahn, Xabier Murgia, Federico Bianco
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 17, p 9597 (2022)
We compared the performance and levofloxacin (Quinsair) lung deposition of three nebulisers commonly used in CF (I-Neb Advance, eFlow rapid, and LC Plus) with the approved nebuliser Zirela. The delivered dose, delivery rate, and aerosol particle size
Externí odkaz:
https://doaj.org/article/ff3065208459491b96fccf9ff7ca6b0b
Autor:
Carsten Schwarz, Claudio Procaccianti, Benjamin Mignot, Hosein Sadafi, Nicolas Schwenck, Xabier Murgia, Federico Bianco
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2051 (2021)
Pulmonary infections caused by Pseudomonas aeruginosa (PA) represent the leading cause of pulmonary morbidity in adults with cystic fibrosis (CF). In addition to tobramycin, colistin, and aztreonam, levofloxacin has been approved in Europe to treat P
Externí odkaz:
https://doaj.org/article/e6749b426fe64a5384b4799e4760582e
Publikováno v:
Elborn, J S, Flume, P A, Van Devanter, D R & Procaccianti, C 2021, ' Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis ', Future microbiology . https://doi.org/10.2217/fmb-2021-0150
People with cystic fibrosis (CF) are highly susceptible to bacterial infections of the airways. By adulthood, chronic Pseudomonas aeruginosa ( Pa) is the most prevalent infective organism and is difficult to eradicate owing to its adaptation to the C
Autor:
Klemens Budde, Lionel Rostaing, Umberto Maggiore, Giovanni Piotti, Daniela Surace, Silvia Geraci, Claudio Procaccianti, Gabriele Nicolini, Oliver Witzke, Nassim Kamar, Laetitia Albano, Matthias Büchler, Julio Pascual, Alex Gutiérrez-Dalmau, Dirk Kuypers, Thomas Wekerle, Maciej Głyda, Mario Carmellini, Giuseppe Tisone, Karsten Midtvedt, Lars Wennberg, Josep M. Grinyó
Background: Tacrolimus is the calcineurin inhibitor of choice for preventing acute rejection episodes in kidney transplant patients. However, tacrolimus has a narrow therapeutic range that requires regular monitoring of blood concentrations to minimi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e8f98fd96d11b4bb074752304d7e9bb
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85128108677
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85128108677
Autor:
Hosein Sadafi, Xabier Murgia, Nicolas Schwenck, Benjamin Mignot, Carsten Schwarz, Claudio Procaccianti, Federico Bianco
Publikováno v:
Pharmaceutics; Volume 13; Issue 12; Pages: 2051
Pharmaceutics, Vol 13, Iss 2051, p 2051 (2021)
Pharmaceutics
Pharmaceutics, Vol 13, Iss 2051, p 2051 (2021)
Pharmaceutics
Pulmonary infections caused by Pseudomonas aeruginosa (PA) represent the leading cause of pulmonary morbidity in adults with cystic fibrosis (CF). In addition to tobramycin, colistin, and aztreonam, levofloxacin has been approved in Europe to treat P
Autor:
Klemens, Budde, Lionel, Rostaing, Umberto, Maggiore, Giovanni, Piotti, Daniela, Surace, Silvia, Geraci, Claudio, Procaccianti, Gabriele, Nicolini, Oliver, Witzke, Nassim, Kamar, Laetitia, Albano, Matthias, Büchler, Julio, Pascual, Alex, Gutiérrez-Dalmau, Dirk, Kuypers, Thomas, Wekerle, Maciej, Głyda, Mario, Carmellini, Giuseppe, Tisone, Karsten, Midtvedt, Lars, Wennberg, Josep M, Grinyó
Publikováno v:
Transplant international : official journal of the European Society for Organ Transplantation. 35
Autor:
Carsten Schwarz, Claudio Procaccianti, Dennis Belmans, Benjamin Mignot, Nicolas Schwenck, Xabier Murgia, Federico Bianco
Publikováno v:
Adult cystic fibrosis (CF).
Publikováno v:
Clinical problems.
Publikováno v:
Future microbiology. 16
People with cystic fibrosis (CF) are highly susceptible to bacterial infections of the airways. By adulthood, chronic
Autor:
Klemens Budde, Claudio Procaccianti, Roberto Morganti, Ulf Meier-Kriesche, Daniel R. Stevens, Barbara Suwelack, Suphamai Bunnapradist
Publikováno v:
Annals of Transplantation
Background A previous phase 3 clinical trial in de novo adult kidney transplant recipients (NCT01187953) compared the efficacy and safety of once-daily LCP-tacrolimus (LCPT) and twice-daily immediate-release tacrolimus (IR-Tac). However, whether the